Meeting
2024 ASCO Genitourinary Cancers Symposium
Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.
Authors
Zin Myint
University of Kentucky, Lexington, KY
Zin Myint , William H St. Clair , Stephen Strup , Patrick J. Hensley , Donglin Yan , Carleton Scott Ellis , Jill Kolesar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05478239
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS350)
DOI
10.1200/JCO.2024.42.4_suppl.TPS350
Abstract #
TPS350
Poster Bd #
R2
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
A single-arm, open-label, phase 2 study evaluating pacritinib for patients with biochemical recurrence after definitive treatment for prostate cancer: Blast study.
First Author: Deepak Kilari
Poster
2014 Genitourinary Cancers Symposium
Results of a phase II trial of docetaxel (DOC), bevacizumab (BEV), and androgen deprivation therapy (ADT) for biochemical relapse (BCR) after definitive local therapy for prostate cancer (PC).
First Author: Rana R. McKay
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial.
First Author: Junlong Zhuang
Poster
2023 ASCO Annual Meeting
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang